Overview
Background
Professor Andrew Barbour is an academic general surgeon who specialises in upper gastrointestinal, pancreatic, melanoma and sarcoma surgery.
On completion of his training, Dr Barbour worked at the Bristol Royal Infirmary as an Upper Gastrointestinal and Hepatobiliary Surgery Fellow and then as a Surgical Oncology Fellow at the Memorial Sloan-Kettering Cancer Centre, New York.
Professor Andrew Barbour specializes in the treatment of oesophageal, gastric, and pancreatic diseases, as well as melanoma and soft tissue tumours. He has expertise in minimally invasive treatments these conditions, including robotic surgery, minimally invasive oesophagectomy, laparoscopic anti-reflux surgery (fundoplication), laparoscopic gastrectomy, and laparoscopic pancreatectomy.
Professor Barbour’s research interests are in the treatment of cancer. His academic interests have encompassed the areas of 1) clinical research, including randomised controlled clinical trials, 2) laboratory based research, including molecular biology pertinent to upper gastrointestinal disease, pancreatic cancer and melanoma, 3) translational research integrating the laboratory and clinical domains, and 4) health-related quality of life and patient reported outcomes research.
As a clinical researcher, Prof Barbour has been active in the conduct of clinical trials at Phase I, II and III levels. He was the Principal Investigator for investigator initiated, multicentre phase II trials in oesophageal (DOCTOR trial) and pancreatic cancer (GAP Trial), funded by the NH&MRC and sponsored by the Australasian Gastrointestinal Trials Group (AGITG). Both of these national trials include biological substudies with tumour tissue and blood banking and subsequent molecular analyses aimed at answering specific questions, including the identification of biomarkers of response to therapy. These studies are aimed at developing personalized, precision therapy for cancer. The DOCTOR trial was the first trial to use PET scans to “tailor” or “personalize” therapy for patients with oesophageal cancer. The GAP trial has shown that pre-operative chemotherapy is a safe strategy for patients with pancreatic cancer. Building on the GAP trial, the AGITG has undertaken the MRFF funded MASTERPLAN clinical trial for pancreatic cancer exploring th e role of stereotactic radiation in pancreatic cancer. Professor Barbour is the Chair of the AGITG Upper GI working party and a member of the AGITG Board.
Prof Barbour is a translational researcher at the School of Medicine, The University of Queensland. He is the head of Surgical Oncology Lab at the School of Medicine. His research has focused on using genomic, epigenomic, mRNA expression and next generation sequencing data to classify oesophageal adenocarcinoma (OAC), pancreatic cancer and melanoma and to identify biomarkers of outcome. His lab team was the first to identify genomic catastrophes as potential drivers for oesophageal adenocarcinoma. In addition, his lab is seeking to identify genetic markers in melanoma that will identify patients at high risk for recurrence following surgery and to identify patients who will benefit from the current exciting advances in treatment for advanced melanoma. His work in melanoma is supported by a Queensland Advancing Clinical Research Fellowship. He was also a member of the Australian Pancreatic Cancer Genome Initiative (APGI) that has published several key studies that have improved our understanding of pancreatic cancer. His lab is currently undertaking studies using next generation sequencing of tumour and circulating tumour DNA. Professor Barbour is the Chief Investigator for the Cancer Evolution Biobank based at the Translational Research Institute. This biobank contains tumour tissue and blood from patients with melanoma, oesophageal or gastric cancer linked to clinical outcomes and supports several research projects.
Availability
- Professor Andrew Barbour is:
- Available for supervision
Fields of research
Qualifications
- Doctor of Philosophy, The University of Queensland
- Faculty of Anaesthetists of the Royal Australasian College of Surgeons, Faculty of Anaesthetists of the Royal Australasian College of Surgeons
Works
Search Professor Andrew Barbour’s works on UQ eSpace
2020
Journal Article
Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma
Kryza, Thomas, Khan, Tashbib, Puttick, Simon, Li, Chao, Sokolowski, Kamil A., Tse, Brian W.C., Cuda, Tahleesa, Lyons, Nicholas, Gough, Madeline, Yin, Julia, Parkin, Ashleigh, Deryugina, Elena I., Quigley, James P., Law, Ruby H.P., Whisstock, James C., Riddell, Andrew D., Barbour, Andrew P., Wyld, David K., Thomas, Paul A., Rose, Stephen, Snell, Cameron E., Pajic, Marina, He, Yaowu and Hooper, John D. (2020). Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics, 10 (9), 4116-4133. doi: 10.7150/thno.43589
2019
Journal Article
Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy
van Hootegem, S. J. M., Smithers, B. M., Gotley, D. C., Brosda, S., Thomson, I. G., Thomas, J. M., Gartside, M. and Barbour, A. P. (2019). Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. Diseases of the Esophagus, 33 (6). doi: 10.1093/dote/doz082
2019
Journal Article
The impact of signet ring cell differentiation on outcome in patients with esophageal and gastroesophageal junction adenocarcinoma
van Hootegem, Sander J. M., Smithers, B. Mark, Gotley, David C., Brosda, Sandra, Thomson, Iain G., Thomas, Janine M., Gartside, Michael, van Lanschot, Jan J. B., Lagarde, Sjoerd M., Wijnhoven, Bas P. L. and Barbour, Andrew P. (2019). The impact of signet ring cell differentiation on outcome in patients with esophageal and gastroesophageal junction adenocarcinoma. Annals of Surgical Oncology, 26 (8), 2375-2384. doi: 10.1245/s10434-019-07322-x
2019
Journal Article
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
Vennin, Claire, Melenec, Pauline, Rouet, Romain, Nobis, Max, Cazet, Aurelie S., Murphy, Kendelle J., Herrmann, David, Reed, Daniel A., Lucas, Morghan C., Warren, Sean C., Elgundi, Zehra, Pinese, Mark, Kalna, Gabriella, Roden, Daniel, Samuel, Monisha, Zaratzian, Anaiis, Grey, Shane T., Da Silva, Andrew, Leung, Wilfred, Mathivanan, Suresh, Wang, Yingxiao, Braithwaite, Anthony W., Christ, Daniel, Benda, Ales, Parkin, Ashleigh, Phillips, Phoebe A., Whitelock, John M., Gill, Anthony J., Sansom, Owen J. ... Australian Pancreatic Genome Initiative (APGI) (2019). CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10 (1) 3637. doi: 10.1038/s41467-019-10968-6
2019
Journal Article
To be or not to be: Non-invasive screening for Barrett’s esophagus, dysplasia and adenocarcinoma
Shah, Alok K., Joshi, Virendra, Hartel, Gunter, Barbour, Andrew P. and Hill, Michelle M. (2019). To be or not to be: Non-invasive screening for Barrett’s esophagus, dysplasia and adenocarcinoma. Translational Gastroenterology and Hepatology, 4 (May) 31, 31-31. doi: 10.21037/tgh.2019.04.08
2019
Journal Article
Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: an Australian multi-center study
Kroon, Hidde M., Coventry, Brendon J., Henderson, Michael A., Barbour, Andrew, Serpell, Jonathan, Smithers, B. Mark and Thompson, John F. (2019). Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: an Australian multi-center study. European Journal of Surgical Oncology, 45 (5), 832-837. doi: 10.1016/j.ejso.2019.02.026
2019
Journal Article
Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples
Newell, Felicity, Patel, Kalpana, Gartside, Michael, Krause, Lutz, Brosda, Sandra, Aoude, Lauren G., Loffler, Kelly A., Bonazzi, Vanessa F., Patch, Ann-Marie, Kazakoff, Stephen H., Holmes, Oliver, Xu, Qinying, Wood, Scott, Leonard, Conrad, Lampe, Guy, Lord, Reginald V., Whiteman, David C., Pearson, John V., Nones, Katia, Waddell, Nicola and Barbour, Andrew P. (2019). Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples. BMC Medical Genomics, 12 (1) 31, 31. doi: 10.1186/s12920-019-0476-9
2019
Journal Article
Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-10-A propensity score matched, single center study
Read, Tavis, Fayers, Warren, Thomas, Janine, Wagels, Michael, Barbour, Andrew and Smithers, B. Mark (2019). Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-10-A propensity score matched, single center study. Journal of Surgical Oncology, 119 (6), 717-727. doi: 10.1002/jso.25373
2018
Journal Article
Evaluation of serum glycoprotein biomarker candidates for detection of esophageal adenocarcinoma and surveillance of Barrett’s esophagus
Shah, Alok K., Hartel, Gunter, Brown, Ian, Winterford, Clay, Na, Renhua, Lê Cao, Kim-Anh, Spicer, Bradley A., Dunstone, Michelle A., Phillips, Wayne A, Lord, Reginald V., Barbour, Andrew P., Watson, David I., Joshi, Virendra, Whiteman, David C. and Hill, Michelle M. (2018). Evaluation of serum glycoprotein biomarker candidates for detection of esophageal adenocarcinoma and surveillance of Barrett’s esophagus. Molecular and Cellular Proteomics, 17 (12), 2324-2334. doi: 10.1074/mcp.ra118.000734
2018
Journal Article
Patterns of failure following dose-escalated chemoradiotherapy for fluorodeoxyglucose positron emission tomography staged squamous cell carcinoma of the oesophagus
Effeney, R., Shaw, T., Burmeister, B. H., Burmeister, E., Harvey, J., Mai, G. T., Thomas, J., Barbour, A. P., Smithers, B. M. and Pryor, D. I. (2018). Patterns of failure following dose-escalated chemoradiotherapy for fluorodeoxyglucose positron emission tomography staged squamous cell carcinoma of the oesophagus. Clinical Oncology, 30 (10), 642-649. doi: 10.1016/j.clon.2018.06.011
2018
Journal Article
Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus
Visser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M. and Barbour, Andrew P. (2018). Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 117 (8), 1687-1696. doi: 10.1002/jso.25089
2018
Journal Article
Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy
Thomson, Iain G., Wallen, Matthew P., Hall, Adrian, Ferris, Rebekah, Gotley, David C., Barbour, Andrew P., Lee, Andrew, Thomas, Janine and Smithers, Bernard M. (2018). Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy. International Journal of Surgery, 53, 86-92. doi: 10.1016/j.ijsu.2018.03.030
2018
Journal Article
Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study
Read, Tavis A., Smith, Aaron, Thomas, Janine, David, Michael, Foote, Matthew, Wagels, Michael, Barbour, Andrew and Smithers, B. Mark (2018). Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study. Journal of Surgical Oncology, 117 (4), 579-587. doi: 10.1002/jso.24921
2018
Journal Article
Breaking bad conduits: 'resleeving' the intrathoracic gastric conduit post oesophagectomy
Evennett, Nicholas J. and Barbour, Andrew P. (2018). Breaking bad conduits: 'resleeving' the intrathoracic gastric conduit post oesophagectomy. ANZ Journal of Surgery, 88 (3), E222-E223. doi: 10.1111/ans.13337
2018
Book Chapter
Thoracoscopic and laparoscopic esophagectomy
Smithers, B. Mark, Thomson, Iain and Barbour, Andrew (2018). Thoracoscopic and laparoscopic esophagectomy. Operative thoracic surgery. (pp. 377-386) edited by Larry R. Kaiser, Sarah K. Thompson and Glyn G. Jamieson. Boca Raton, FL, United States: CRC Press. doi: 10.1201/9781315113777
2018
Conference Publication
Neoadjuvant therapy for esophageal adenocarcinoma: a propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy
Barbour, A. P., Brosda, S., Wijnhoven, B., van Hootgem, S., Lanschot, J. J. B., Barbour, S., Lagarde, S., Krause, L., Pryor, D., Thomas, J., Walpole, E. T., van der Gaast, A. and Smithers, M. (2018). Neoadjuvant therapy for esophageal adenocarcinoma: a propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy. 43rd ESMO Congress (ESMO), Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy282.015
2017
Journal Article
Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma
Nepal, Chirag, O'Rourke, Colm J., Oliveira, Douglas Vnp, Taranta, Andrzej, Shema, Steven, Gautam, Prson, Calderaro, Julien, Barbour, Andrew, Raggi, Chiara, Wennerberg, Krister, Wang, Xin W., Lautem, Anja, Roberts, Lewis R. and Andersen, Jesper B. (2017). Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma. Hepatology (Baltimore, Md.), 68 (3), 949-963. doi: 10.1002/hep.29764
2017
Journal Article
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Balachandran, Vinod P., Łuksza, Marta, Zhao, Julia N., Makarov, Vladimir, Moral, John Alec, Remark, Romain, Herbst, Brian, Askan, Gokce, Bhanot, Umesh, Senbabaoglu, Yasin, Wells, Daniel K., Cary, Charles Ian Ormsby, Grbovic-Huezo, Olivera, Attiyeh, Marc, Medina, Benjamin, Zhang, Jennifer, Loo, Jennifer, Saglimbeni, Joseph, Abu-Akeel, Mohsen, Zappasodi, Roberta, Riaz, Nadeem, Smoragiewicz, Martin, Larkin Kelley, Z., Basturk, Olca, Gönen, Mithat, Levine, Arnold J., Allen, Peter J., Fearon, Douglas T., Merad, Miriam ... Bassi, Claudio (2017). Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551 (7681), 512-516. doi: 10.1038/nature24462
2017
Journal Article
Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study
Kroon, Hidde M., Coventry, Brendon J., Giles, Mitchell H., Henderson, Michael A., Speakman, David, Wall, Mark, Barbour, Andrew, Serpell, Jonathan, Paddle, Paul, Smithers, Bernard M. and Thompson, John F. (2017). Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Annals of Surgical Oncology, 24 (11), 3245-3251. doi: 10.1245/s10434-017-6046-5
2017
Journal Article
When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'
Gyorki, David E., Barbour, Andrew, Hanikeri, Mark, Mar, Victoria, Sandhu, Shahneen and Thompson, John F. (2017). When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'. Australasian Journal of Dermatology, 58 (4), 274-277. doi: 10.1111/ajd.12662
Funding
Current funding
Past funding
Supervision
Availability
- Professor Andrew Barbour is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Haressing tumour immune responses in oesophageal cancer: towards better personalised therapeutic strategies
Principal Advisor
Other advisors: Dr Sandra Brosda
-
Doctor Philosophy
Deep spatial phenotyping analysis to characterize cancer evolution
Associate Advisor
Other advisors: Dr Sandra Brosda
-
Doctor Philosophy
Immune regulation through bi-directional interactions between subsets of Natural Killer cells and Dendritic cells.
Associate Advisor
Other advisors: Dr Arutha Kulasinghe, Dr Camille Guillerey, Dr Gustavo Rodrigues Rossi, Associate Professor Fernando Guimaraes
-
Master Philosophy
Retroperitoneal sarcoma: Impact of the patterns of care on patient outcomes in Queensland.
Associate Advisor
Completed supervision
-
2020
Doctor Philosophy
Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma
Principal Advisor
-
2013
Doctor Philosophy
Genomic investigations in oesophageal adenocarcinoma: towards biomarkers of prognosis
Principal Advisor
-
2019
Doctor Philosophy
Human dendritic cell immunoprofiling in advanced melanoma patients and responses to immunotherapy
Associate Advisor
Other advisors: Honorary Professor Kristen Radford
-
2019
Doctor Philosophy
Lipid Metabolism in Barrett's Esophagus and Esophageal Adenocarcinoma
Associate Advisor
-
2016
Doctor Philosophy
In vitro and in vivo evaluation of alginate-based microparticles for oral delivery of active entities to sites of inflammation in the colon
Associate Advisor
Other advisors: Professor Peter Cabot
-
2015
Doctor Philosophy
Serum diagnostic glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinoma
Associate Advisor
Media
Enquiries
For media enquiries about Professor Andrew Barbour's areas of expertise, story ideas and help finding experts, contact our Media team: